Ivermectin in Prevention and Treatment of COVID-19

Phase 3

Recruiting

• Conditions: Suspected of SARS-CoV-2 infection; SARS-CoV-2 infection, COVID-19, Ivermectin

• Registration Number: TCTR20210929002
• Lead Sponsor: Faculty of Medicine Siriraj Hospital, Mahidol university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-29
• Study Completion: 2021-10-15
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1.Patients with respiratory tract symptoms or fever, or asymptomatic and contact with confirmed COVID-19 at outpatients clinic
2.Performed nasopharyngeal swab for PCR-COVID on the enrollment date
3. Available for telephone interview
4.Able to sign written informed consent

Exclusion Criteria

1. Previous COVID-19 infection within 90 days before enrollment
2. Pregnancy and/or lactation
3. Allergy to Ivermectin or drugs with gamma-aminobutyric acid (GABA) potentiating activity and/or altered p-glycoprotein transport system

Study & Design

• Study Type: Interventional
• Study Design: Not specified